company background image
EMMA

Emmaus Life Sciences OTCPK:EMMA Stock Report

Last Price

US$0.31

Market Cap

US$16.6m

7D

3.3%

1Y

-16.2%

Updated

29 May, 2023

Data

Company Financials

Emmaus Life Sciences, Inc.

OTCPK:EMMA Stock Report

Mkt Cap: US$16.6m

EMMA Stock Overview

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.

EMMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Emmaus Life Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Emmaus Life Sciences
Historical stock prices
Current Share PriceUS$0.31
52 Week HighUS$0.60
52 Week LowUS$0.071
Beta1.92
1 Month Change-1.59%
3 Month Change-18.42%
1 Year Change-16.22%
3 Year Change-80.75%
5 Year Changen/a
Change since IPO-96.84%

Recent News & Updates

Recent updates

Shareholder Returns

EMMAUS PharmaceuticalsUS Market
7D3.3%-2.7%0.06%
1Y-16.2%-4.9%-0.7%

Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned -4.9% over the past year.

Return vs Market: EMMA underperformed the US Market which returned -0.7% over the past year.

Price Volatility

Is EMMA's price volatile compared to industry and market?
EMMA volatility
EMMA Average Weekly Movement14.3%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.5%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: EMMA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: EMMA's weekly volatility has decreased from 26% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200055Yutaka Niiharahttps://www.emmausmedical.com

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.

Emmaus Life Sciences, Inc. Fundamentals Summary

How do Emmaus Life Sciences's earnings and revenue compare to its market cap?
EMMA fundamental statistics
Market CapUS$16.63m
Earnings (TTM)-US$12.61m
Revenue (TTM)US$21.91m

0.8x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EMMA income statement (TTM)
RevenueUS$21.91m
Cost of RevenueUS$2.01m
Gross ProfitUS$19.90m
Other ExpensesUS$32.51m
Earnings-US$12.61m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin90.83%
Net Profit Margin-57.56%
Debt/Equity Ratio-83.2%

How did EMMA perform over the long term?

See historical performance and comparison